Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* previously untreated participants with cluster of differentiation 20 (CD20) positive B-cell chronic lymphocytic leukemia;~* participants with progressive Binet stage B, or C requiring therapy according to National Cancer Institute (NCI) criteria;~* Eastern Cooperative Oncology Group (ECOG) performance status \<=2.~Exclusion Criteria:~* previous treatment for Chronic Lymphocytic Leukaemia (CLL);~* known concomitant hematological malignancy;~* transformation to aggressive B-cell malignancy;~* history of severe cardiac disease;~* known hypersensitivity or anaphylactic reactions to murine antibodies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab plus Chlorambucil (Type: EXPERIMENTAL): Participants will receive combination therapy of rituximab plus chlorambucil for first 6 cycles and then chlorambucil alone for a maximum of 6 additional cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).